Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELIEHF: Patiromer for MRA Optimization in Heart Failure
NCT04142788Phase 4Terminated
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Aug 2020
- Primary completion
- Dec 2022
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of patiromer in heart failure (HF) (2 arms), sponsored by NHS Greater Glasgow and Clyde. Primary endpoints: Congestion Index at Day 60 and Morbidity and Mortality up to 10 years. Started Aug 2020; status: terminated.
02
Drugs
patiromer
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT04142788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04142788.